Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 12/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.35 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12300587 | 0.87 | QPCT (0.44) | QPCTIP6K1 | |
| SCHEMBL12301392 | 0.87 | QPCT (0.39) | MMP12QPCTIP6K1QPCTL | |
| SCHEMBL12300584 | 0.83 | QPCT (0.40) | QPCTQPCTL | |
| SCHEMBL12299659 | 0.81 | QPCT (0.42) | MMP12QPCTQPCTL | |
| SCHEMBL13643310 | 0.79 | QPCT (0.51) | QPCTIP6K1QPCTL | |
| SCHEMBL12344414 | 0.77 | QPCT (0.42) | QPCTQPCTLHSD11B1 | |
| SCHEMBL12344548 | 0.76 | QPCT (0.52) | QPCTQPCTL | |
| SCHEMBL12299666 | 0.76 | QPCT (0.42) | QPCTQPCTL | |
| SCHEMBL2380742 | 0.75 | QPCT (0.46) | QPCTIP6K1IP6K3QPCTL | |
| SCHEMBL13643286 | 0.74 | QPCT (0.53) | QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283259-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | MMP12 3622/4885QPCT 2/4885IP6K1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.